Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HealthEquityFRA:2HE 93 3-1 Month Momentum % is 13.64% as of Sep. 03, 2026. GuruFocus rates FRA:2HE with a GF Score™ of 93/100 and a GF Value™ of €92.70 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 665 Healthcare Providers & Services companies, HealthEquity ranks better than 83.01% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-03), HealthEquity's 3-1 Month Momentum % is 13.64%.
The industry rank for HealthEquity's 3-1 Month Momentum % or its related term are showing as below:
FRA:2HE's 3-1 Month Momentum % is ranked better than 83.01% of 665
companies
in the Healthcare Providers & Services industry
Industry Median: -1.01
vs FRA:2HE: 13.64
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
HealthEquity 3-1 Month Momentum % Related Terms
FRA:2HE vs TXG, HNGE, WAY: 3-1 Month Momentum % Comparison
For the Health Information Services subindustry, HealthEquity's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HealthEquity 3-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, HealthEquity's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where HealthEquity's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HealthEquity (FRA:2HE) has a 3-1 Month Momentum % of 13.64% as of Sep. 03, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on HealthEquity and its competitors. According to the industry distribution chart, HealthEquity ranks #113 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 17%.
Is HealthEquity's 3-1 Month Momentum % too high?
HealthEquity's current 3-1 Month Momentum % is 13.64%. Based on the distribution chart, HealthEquity ranks #113 out of 665 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, HealthEquity has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HealthEquity's 3-1 Month Momentum % compare to TXG and HNGE?
According to the Healthcare Providers & Services industry distribution chart, HealthEquity ranks #113 out of 665 companies for 3-1 Month Momentum %. This places HealthEquity in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
A good 3-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on HealthEquity and its competitors. HealthEquity's current 3-1 Month Momentum % is 13.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HealthEquity stock overvalued right now?
Based on GuruFocus' analysis, HealthEquity (FRA:2HE) is currently considered Modestly Undervalued. The stock's GF Value™ is €92.70, compared to a current price of €82.50 — trading 11% below its estimated fair value. The current 3-1 Month Momentum % is 13.64%. HealthEquity's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For HealthEquity (FRA:2HE), the current 3-1 Month Momentum % is 13.64% as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HealthEquity (FRA:2HE) Overvalued in 2026?
Based on GuruFocus' analysis, HealthEquity stock appears to be undervalued.
The current stock price of €82.50 is trading 11% below its estimated GF Value™ of €92.70.
GuruFocus considers HealthEquity to be Modestly Undervalued.
Key valuation signals for FRA:2HE:
3-1 Month Momentum %: 13.64%
GF Value™: €92.70 vs. price of €82.50 (11% below fair value)
No single metric tells the full story. See the FRA:2HE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
93GF Score
Get the complete analysis for FRA:2HE
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2HE has been successfully added to your 
